schliessen

Filtern

 

Bibliotheken

Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach

•A lot of clinically relevant cancers lack ideal targets.•Chemotherapy-induced apoptosis for in situ antigen generation could enhance TLR agonist.•Lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared.•LPC+CpG-Lipo combination therapy exhibited synergisti... Full description

Journal Title: Cancer Letters 28 August 2016, Vol.379(1), pp.32-38
Main Author: Lu, Yao
Other Authors: Wang, Yuhua , Miao, Lei , Haynes, Matthew , Xiang, Guangya , Huang, Leaf
Format: Electronic Article Electronic Article
Language: English
Subjects:
Lpc
ID: ISSN: 0304-3835 ; DOI: 10.1016/j.canlet.2016.05.025
Link: http://dx.doi.org/10.1016/j.canlet.2016.05.025
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: sciversesciencedirect_elsevierS0304-3835(16)30338-X
title: Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
format: Article
creator:
  • Lu, Yao
  • Wang, Yuhua
  • Miao, Lei
  • Haynes, Matthew
  • Xiang, Guangya
  • Huang, Leaf
subjects:
  • Cisplatin Nanoparticle
  • Cpg-Odn
  • Melanoma
  • Immunotherapy
  • Chemotherapy
  • Cddp
  • Cpg-Lipo
  • Lpc
  • Lpc+Cpg-Lipo
ispartof: Cancer Letters, 28 August 2016, Vol.379(1), pp.32-38
description: •A lot of clinically relevant cancers lack ideal targets.•Chemotherapy-induced apoptosis for in situ antigen generation could enhance TLR agonist.•Lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared.•LPC+CpG-Lipo combination therapy exhibited synergistic CTL response.•LPC+CpG-Lipo combination therapy established strong synergistic effect in abrogation of tumor growth. Therapeutic anticancer vaccine development must address a number of barriers to achieve successful tumor specific killing, including effective antigen presentation and antigen-specific T-cell activation to mediate cytotoxic cellular effects, inhibition of an immune-suppressive tumor microenvironment in order to facilitate and enhance CTL activity, and induction of memory T-cells to prolong tumor rejection. While traditional as well as modern vaccines rely upon delivery of both antigen and adjuvant, a variety of clinically relevant cancers lack ideal immunogenic antigens. Building upon recent efforts, we instead chose to exploit chemotherapy-induced apoptosis to allow for in situ antigen generation in a combination, nanomedicine-based approach. Specifically, lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared for the temporally-controlled and multifaceted treatment of an advanced in vivo model of melanoma. Such combination therapy established strong synergistic effects, both in apoptotic extent and subsequent abrogation of tumor growth, which were due largely to both an enhanced cytotoxic T-cell recruitment and a reduction of immune-suppressive mediators in the microenvironments of both spleens and tumor. These results underlie a prolonged host lifespan in the combination approach (45 days) as compared with control (25 days, p 
language: eng
source:
identifier: ISSN: 0304-3835 ; DOI: 10.1016/j.canlet.2016.05.025
fulltext: fulltext
issn:
  • 03043835
  • 0304-3835
url: Link


@attributes
ID1181816339
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidS0304-3835(16)30338-X
sourceidsciversesciencedirect_elsevier
recordidTN_sciversesciencedirect_elsevierS0304-3835(16)30338-X
sourcesystemOther
pqid1808701138
galeid471613805
display
typearticle
titleExploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
creatorLu, Yao ; Wang, Yuhua ; Miao, Lei ; Haynes, Matthew ; Xiang, Guangya ; Huang, Leaf
ispartofCancer Letters, 28 August 2016, Vol.379(1), pp.32-38
identifierISSN: 0304-3835 ; DOI: 10.1016/j.canlet.2016.05.025
subjectCisplatin Nanoparticle ; Cpg-Odn ; Melanoma ; Immunotherapy ; Chemotherapy ; Cddp ; Cpg-Lipo ; Lpc ; Lpc+Cpg-Lipo
description•A lot of clinically relevant cancers lack ideal targets.•Chemotherapy-induced apoptosis for in situ antigen generation could enhance TLR agonist.•Lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared.•LPC+CpG-Lipo combination therapy exhibited synergistic CTL response.•LPC+CpG-Lipo combination therapy established strong synergistic effect in abrogation of tumor growth. Therapeutic anticancer vaccine development must address a number of barriers to achieve successful tumor specific killing, including effective antigen presentation and antigen-specific T-cell activation to mediate cytotoxic cellular effects, inhibition of an immune-suppressive tumor microenvironment in order to facilitate and enhance CTL activity, and induction of memory T-cells to prolong tumor rejection. While traditional as well as modern vaccines rely upon delivery of both antigen and adjuvant, a variety of clinically relevant cancers lack ideal immunogenic antigens. Building upon recent efforts, we instead chose to exploit chemotherapy-induced apoptosis to allow for in situ antigen generation in a combination, nanomedicine-based approach. Specifically, lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared for the temporally-controlled and multifaceted treatment of an advanced in vivo model of melanoma. Such combination therapy established strong synergistic effects, both in apoptotic extent and subsequent abrogation of tumor growth, which were due largely to both an enhanced cytotoxic T-cell recruitment and a reduction of immune-suppressive mediators in the microenvironments of both spleens and tumor. These results underlie a prolonged host lifespan in the combination approach (45 days) as compared with control (25 days, p < 0.02), providing promise toward a personalized approach to nanomedicine by establishing effect synergy in host-specific immunotherapy following chemotherapy.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1016/j.canlet.2016.05.025$$EView_record_in_ScienceDirect
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Lu, Yao
1Wang, Yuhua
2Miao, Lei
3Haynes, Matthew
4Xiang, Guangya
5Huang, Leaf
titleExploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
description•A lot of clinically relevant cancers lack ideal targets.•Chemotherapy-induced apoptosis for in situ antigen generation could enhance TLR agonist.•Lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared.•LPC+CpG-Lipo combination therapy exhibited synergistic CTL response.•LPC+CpG-Lipo combination therapy established strong synergistic effect in abrogation of tumor growth. Therapeutic anticancer vaccine development must address a number of barriers to achieve successful tumor specific killing, including effective antigen presentation and antigen-specific T-cell activation to mediate cytotoxic cellular effects, inhibition of an immune-suppressive tumor microenvironment in order to facilitate and enhance CTL activity, and induction of memory T-cells to prolong tumor rejection. While traditional as well as modern vaccines rely upon delivery of both antigen and adjuvant, a variety of clinically relevant cancers lack ideal immunogenic antigens. Building upon recent efforts, we instead chose to exploit chemotherapy-induced apoptosis to allow for in situ antigen generation in a combination, nanomedicine-based approach. Specifically, lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared for the temporally-controlled and multifaceted treatment of an advanced in vivo model of melanoma. Such combination therapy established strong synergistic effects, both in apoptotic extent and subsequent abrogation of tumor growth, which were due largely to both an enhanced cytotoxic T-cell recruitment and a reduction of immune-suppressive mediators in the microenvironments of both spleens and tumor. These results underlie a prolonged host lifespan in the combination approach (45 days) as compared with control (25 days, p < 0.02), providing promise toward a personalized approach to nanomedicine by establishing effect synergy in host-specific immunotherapy following chemotherapy.
subject
0Cisplatin Nanoparticle
1Cpg-Odn
2Melanoma
3Immunotherapy
4Chemotherapy
5Cddp
6Cpg-Lipo
7Lpc
8Lpc+Cpg-Lipo
general
0English
1Elsevier Ireland Ltd
210.1016/j.canlet.2016.05.025
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidsciversesciencedirect_elsevier
recordidsciversesciencedirect_elsevierS0304-3835(16)30338-X
issn
003043835
10304-3835
rsrctypearticle
creationdate2016
addtitleCancer Letters
searchscope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
scope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
startdate20160828
enddate20160828
citationpf 32 pt 38 vol 379 issue 1
lsr30VSR-Enriched:[galeid, pqid, eissn]
sort
titleExploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
authorLu, Yao ; Wang, Yuhua ; Miao, Lei ; Haynes, Matthew ; Xiang, Guangya ; Huang, Leaf
creationdate20160828
lso0120160828
facets
frbrgroupid5652735637957121199
frbrtype5
languageeng
creationdate2016
topic
0Cisplatin Nanoparticle
1Cpg-Odn
2Melanoma
3Immunotherapy
4Chemotherapy
5Cddp
6Cpg-Lipo
7Lpc
8Lpc+Cpg-Lipo
collectionScienceDirect Journals (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Lu, Yao
1Wang, Yuhua
2Miao, Lei
3Haynes, Matthew
4Xiang, Guangya
5Huang, Leaf
jtitleCancer Letters
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Lu
1Wang
2Miao
3Haynes
4Xiang
5Huang
aufirstYao
au
0Lu, Yao
1Wang, Yuhua
2Miao, Lei
3Haynes, Matthew
4Xiang, Guangya
5Huang, Leaf
atitleExploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
jtitleCancer Letters
risdate20160828
volume379
issue1
spage32
epage38
pages32-38
issn0304-3835
formatjournal
genrearticle
ristypeJOUR
abstract•A lot of clinically relevant cancers lack ideal targets.•Chemotherapy-induced apoptosis for in situ antigen generation could enhance TLR agonist.•Lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared.•LPC+CpG-Lipo combination therapy exhibited synergistic CTL response.•LPC+CpG-Lipo combination therapy established strong synergistic effect in abrogation of tumor growth. Therapeutic anticancer vaccine development must address a number of barriers to achieve successful tumor specific killing, including effective antigen presentation and antigen-specific T-cell activation to mediate cytotoxic cellular effects, inhibition of an immune-suppressive tumor microenvironment in order to facilitate and enhance CTL activity, and induction of memory T-cells to prolong tumor rejection. While traditional as well as modern vaccines rely upon delivery of both antigen and adjuvant, a variety of clinically relevant cancers lack ideal immunogenic antigens. Building upon recent efforts, we instead chose to exploit chemotherapy-induced apoptosis to allow for in situ antigen generation in a combination, nanomedicine-based approach. Specifically, lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared for the temporally-controlled and multifaceted treatment of an advanced in vivo model of melanoma. Such combination therapy established strong synergistic effects, both in apoptotic extent and subsequent abrogation of tumor growth, which were due largely to both an enhanced cytotoxic T-cell recruitment and a reduction of immune-suppressive mediators in the microenvironments of both spleens and tumor. These results underlie a prolonged host lifespan in the combination approach (45 days) as compared with control (25 days, p < 0.02), providing promise toward a personalized approach to nanomedicine by establishing effect synergy in host-specific immunotherapy following chemotherapy.
pubElsevier Ireland Ltd
doi10.1016/j.canlet.2016.05.025
eissn18727980
date2016-08-28